NCCN and Experts from China Collaborate to Develop Colon, Kidney, Non-Small Cell Lung, and Ovarian Cancer Guidelines, Chin

NCCN announces the launch of the NCCN Guidelines – China Editions for Colon, Kidney, Non-Small Cell Lung, and Ovarian Cancers, which have been translated into Chinese and reflect regional adaptations. These Guidelines are now available on

FORT WASHINGTON, Pa.--(BUSINESS WIRE)-- The National Comprehensive Cancer Network® (NCCN®) announces the launch of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) – China Editions for Colon, Kidney, Non-Small Cell Lung, and Ovarian Cancers, which have been translated into Chinese and are now available on Based on the NCCN Guidelines, the China Editions comprise the extensive expertise of more than 100 Chinese cancer specialists in collaboration with NCCN panel experts. The China Editions contain recommendations revised to account for genetic, pharmacological, and regulatory considerations of the Chinese population.

These latest China Editions add to an already extensive list of Chinese translations of the NCCN Guidelines, including those for Breast, Cervical, Gastric, Head & Neck, Pancreatic, and Rectal Cancers, Adult Cancer Pain, and Non-Hodgkin’s Lymphomas, all of which are also available on

The NCCN Guidelines are the recognized standard for clinical policy in oncology in the United States. Expert clinicians across Asia recognize and apply the NCCN Guidelines in practice and have collaborated with NCCN on the translation, adaptation, and implementation of national versions of the NCCN Guidelines. NCCN and cancer-care thought leaders in China have had a long-standing collaboration in the development of the NCCN Guidelines – China Editions - the most authoritative reference for oncology practice in China. Indeed, of the 1.1 million unique visitors to the NCCN website ( every year, almost 300,000 are from Asian countries. Forty-six thousand unique visitors are from China.

NCCN regularly collaborates with international organizations around the world to create and distribute translations of the NCCN Guidelines, which may include modifications representative of metabolic differences in populations, technological considerations, and regulatory status of agents used in cancer management, such as availabilities of drugs, biologics, devices, and procedures.

To view the NCCN Guidelines – China Editions for Colon, Kidney, Non-Small Cell Lung, and Ovarian Cancers, visit

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas MD Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

Clinicians, visit Patients and caregivers, visit


Carrie Capili, 215-690-0238
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  China  Pennsylvania

INDUSTRY KEYWORDS:   Health  Public Policy/Government  Healthcare Reform  Oncology  Pharmaceutical  Public Policy  General Health